DE2622123A1 - Prostaglandin-analoge - Google Patents

Prostaglandin-analoge

Info

Publication number
DE2622123A1
DE2622123A1 DE19762622123 DE2622123A DE2622123A1 DE 2622123 A1 DE2622123 A1 DE 2622123A1 DE 19762622123 DE19762622123 DE 19762622123 DE 2622123 A DE2622123 A DE 2622123A DE 2622123 A1 DE2622123 A1 DE 2622123A1
Authority
DE
Germany
Prior art keywords
carbon atoms
formula
general formula
stands
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19762622123
Other languages
German (de)
English (en)
Inventor
Masaki Hayashi
Seiji Kori
Hajimu Miyake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ono Pharmaceutical Co Ltd
Original Assignee
Ono Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co Ltd filed Critical Ono Pharmaceutical Co Ltd
Publication of DE2622123A1 publication Critical patent/DE2622123A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE19762622123 1975-06-16 1976-05-18 Prostaglandin-analoge Ceased DE2622123A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB25591/75A GB1520522A (en) 1975-06-16 1975-06-16 16-methyleneprostaglandins

Publications (1)

Publication Number Publication Date
DE2622123A1 true DE2622123A1 (de) 1976-12-30

Family

ID=10230162

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19762622123 Ceased DE2622123A1 (de) 1975-06-16 1976-05-18 Prostaglandin-analoge

Country Status (5)

Country Link
US (1) US4018812A (enExample)
JP (1) JPS51149247A (enExample)
DE (1) DE2622123A1 (enExample)
FR (1) FR2314712A2 (enExample)
GB (1) GB1520522A (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0625123B2 (ja) * 1985-12-12 1994-04-06 大塚製薬株式会社 カルボスチリル誘導体−シクロデキストリン包接化合物
PL350917A1 (en) 1999-03-05 2003-02-10 Procter & Gamble C16 unsaturated fp-selective prostaglandins analogs
HUP0200365A2 (hu) * 1999-03-05 2002-07-29 The Procter & Gamble Co. C16-telítetlen prosztaglandin analógok és alkalmazásuk
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20050227187A1 (en) * 2002-03-04 2005-10-13 Supercritical Systems Inc. Ionic fluid in supercritical fluid for semiconductor processing
US20060102282A1 (en) * 2004-11-15 2006-05-18 Supercritical Systems, Inc. Method and apparatus for selectively filtering residue from a processing chamber
US20060185693A1 (en) * 2005-02-23 2006-08-24 Richard Brown Cleaning step in supercritical processing
US20060185694A1 (en) * 2005-02-23 2006-08-24 Richard Brown Rinsing step in supercritical processing
US7550075B2 (en) * 2005-03-23 2009-06-23 Tokyo Electron Ltd. Removal of contaminants from a fluid
US20060226117A1 (en) * 2005-03-29 2006-10-12 Bertram Ronald T Phase change based heating element system and method
US20060225769A1 (en) * 2005-03-30 2006-10-12 Gentaro Goshi Isothermal control of a process chamber
US8722739B2 (en) * 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1356581A (en) * 1970-10-09 1974-06-12 Ici Ltd Cyclopentane derivatives
GB1449882A (en) * 1973-08-31 1976-09-15 Ono Pharmaceutical Co Prostaglandin analogues

Also Published As

Publication number Publication date
JPS51149247A (en) 1976-12-22
US4018812A (en) 1977-04-19
FR2314712A2 (fr) 1977-01-14
GB1520522A (en) 1978-08-09
FR2314712B2 (enExample) 1978-12-08

Similar Documents

Publication Publication Date Title
DE2622123A1 (de) Prostaglandin-analoge
DE2902442A1 (de) 9-deoxy-9a-methylen-isostere von pgi tief 2 , verfahren zu ihrer herstellung und sie enthaltende pharmazeutische und veterinaermedizinische mittel
DE2605584A1 (de) Prostaglandin-analoge
DE3118360C2 (enExample)
DE2409460A1 (de) Prostaglandinverbindungen und verfahren zu ihrer herstellung
CH626876A5 (enExample)
DE2365035A1 (de) Prostaglandin-analoge
DE2416193C2 (de) Prostaglandin-Analoge, Verfahren zu ihrer Herstellung sowie ihre Verwendung als cytoprotektives Mittel
DE2505519A1 (de) Prostaglandinanaloge, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE2347630A1 (de) Prostaglandin-analoge
DE2515770C2 (de) Prostaglandinanaloge, Verfahren zu ihrer Herstellung und sie enthaltende Arzneimittel
DE2510818C2 (de) Neue Prostaglandin-Analoge sowie ein Verfahren zu deren Herstellung, sowie Arzneimittel die diese enthalten
DE2460285A1 (de) Trans-delta hoch 2-prostaglandinverbindungen, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE2627672A1 (de) Prostaglandinartige 1,15-lactone und verfahren zu deren herstellung
DE2631894A1 (de) Prostaglandin-analoge
DE2500451A1 (de) Prostaglandinanaloge, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3002677A1 (de) Prostaglandin-analoge
DE2910474C2 (enExample)
DE2825440C2 (de) Prostaglandin-Analoge, Verfahren zu ihrer Herstellung, sowie diese enthaltende pharmazeutische Zusammensetzungen
DE2830478C2 (de) Prostaglandin-Analoge
DE2440919A1 (de) Prostaglandinanaloge, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE2640692C3 (de) Optisch aktive 5- (2-Carboxythiophen5-yl)-16phenoxy- a -tetranor- w tetranor-prostaglandine
DE2524955C3 (de) Neue Thienyl-Prostaglandine und Verfahren zu ihrer Herstellung
DE2634866A1 (de) Prostaglandin-analoge
DE2733976A1 (de) Neue cyanprostaglandine und verfahren zu deren herstellung

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: HENKEL, G., DR.PHIL. FEILER, L., DR.RER.NAT. HAENZ

8131 Rejection